We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Phase Ib trial of intravenous recombinant humanized monoclonal antibody to vascular endothelial growth factor in combination with chemotherapy in patients with advanced cancer: pharmacologic and long-term safety data.
- Authors
Margolin, K; Gordon, M S; Holmgren, E; Gaudreault, J; Novotny, W; Fyfe, G; Adelman, D; Stalter, S; Breed, J
- Abstract
Tumor angiogenesis mediated by vascular endothelial growth factor (VEGF) is inhibited by the recombinant humanized (rhu) monoclonal antibody (MAb) rhuMAbVEGF, which has synergy with chemotherapy in animal models. The present study was designed to assess the safety and pharmacokinetics of weekly intravenous (IV) rhuMAbVEGF with one of three standard chemotherapy regimens.
- Publication
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2001, Vol 19, Issue 3, p851
- ISSN
0732-183X
- Publication type
Journal Article
- DOI
10.1200/JCO.2001.19.3.851